

The Dotti estradiol patch shortage continues in 2026. Get the latest update on why it's happening, what it costs, and how to find it in stock.
If you rely on Dotti estradiol patches and have been told your pharmacy can't fill your prescription, you're living through one of the most significant hormone therapy shortages in years. In this post, we'll give you a clear, honest update on the Dotti shortage as of early 2026 — what's causing it, how long it might last, and what you can do right now.
Yes. As of February 2026, Dotti and other estradiol transdermal patches remain in shortage across much of the United States. The shortage is not limited to Dotti — it affects multiple estradiol patch brands and generics, though some products are harder to find than others.
The FDA is aware of the situation and has stated it is monitoring estradiol patch supply. However, no official resolution date has been announced. Reports from pharmacies, patients, and wholesalers all confirm that supply remains significantly below demand.
The current shortage is the result of a perfect storm. Here are the main drivers:
In November 2025, the FDA removed the longstanding black box warning from bioidentical estradiol patches, gels, and creams. This warning — in place for over two decades — had overstated the risks of hormone replacement therapy (HRT) and discouraged millions of women and their doctors from using it.
Once the warning was removed, demand for HRT surged. Women who had been suffering through menopause symptoms without treatment began asking their doctors for prescriptions. The result: a massive spike in estradiol patch prescriptions that manufacturers were not prepared to handle.
Even before the FDA's decision, demand had been rising steadily. Telehealth menopause companies like Midi Health, Alloy, and Evernow made HRT more accessible starting around 2020. Social media also played a role, with more women sharing their positive experiences with hormone therapy. The black box removal was the catalyst, but the trend had been building for years.
Estradiol transdermal patches are complex to manufacture. They require specialized facilities and processes, and only a small number of companies produce them. Amneal Pharmaceuticals (which makes Dotti) and a few other manufacturers cannot simply double their output overnight. Scaling up production takes time — often 6 to 18 months.
The shortage has not significantly changed Dotti's pricing, but availability issues mean you may not always be able to shop for the best deal. Here's what to expect:
If cost is a barrier, see our full guide: How to Save Money on Dotti in 2026.
While no brand-new estradiol patch products have launched to address the shortage, patients do have several options:
For a detailed comparison, read Alternatives to Dotti If You Can't Fill Your Prescription.
Even during the shortage, Dotti is not completely unavailable — it just requires more effort to find. Here's what works:
For the full playbook, see How to Find Dotti in Stock Near You.
The 2026 Dotti shortage is frustrating, but it's important to know that you have options and you don't have to go without hormone therapy. The shortage is driven by increased demand — which, in many ways, is a positive sign that more women are getting the treatment they need. The supply just hasn't caught up yet.
Stay proactive: use Medfinder to track availability, talk to your doctor about alternatives, and don't wait until your last patch to start looking for a refill. If you're a provider, check out our provider briefing on the Dotti shortage for clinical guidance.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.